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Abstract
Background Second-generation cryoballoon based pul-
monary vein isolation has demonstrated encouraging acute
and mid-term clinical outcome. Customarily, a bonus-
freeze is applied after successful pulmonary vein isolation.
Objective To compare the long-term clinical outcome
and safety profile of a bonus-freeze and a no bonus-freeze
protocol.
Methods A total of 120 consecutive patients with
paroxysmal [95/120 (79 %)] or persistent atrial fibrillation
[25/120 (21 %)] underwent CB2-based PVI. Freeze-cycle
duration was 240 s. In the first 60 patients a bonus-freeze
was applied after successful PVI (group 1), while in the
following 60 patients the bonus-freeze was omitted (group
2).
Results Procedure and fluoroscopy times were signifi-
cantly shorter in group 2 [113.8 ± 32 vs 138.2 ± 29 min
(p = 0.03) and 19.2 ± 6 vs 24.3 ± 8 min (p = 0.02)]. No
differences in procedural complications were found. Dur-
ing a mean follow-up of 849 ± 74 (group 1) and
848 ± 101 days (group 2, p = 0.13) 69 % of patients
(group 1) and 67 % of patients (group 2) remained in
stable sinus rhythm without any differences between the
groups (p = 0.69).
Conclusions Freedom from atrial fibrillation after sec-
ond-generation cryoballoon based pulmonary vein isolation
and a follow-up of[2 years is comparable when applying
a bonus- and a no bonus-freeze protocol, while procedure
and fluoroscopy times are significantly shorter when
omitting the bonus-freeze. No differences in periprocedural
complications were identified.
Keywords Atrial fibrillation  Pulmonary vein isolation 
Cryoballoon  Long-term follow-up
Introduction
Second-generation cryoballoon (CB2, Arctic Front
Advance, Medtronic, Inc., Minneapolis, MN, USA)-based
pulmonary vein isolation (PVI) has demonstrated high
procedural success rates and encouraging clinical outcome
data for patients with paroxysmal (PAF) and persistent
atrial fibrillation (PersAF) [1–7]. Current ablation strate-
gies are commonly based on a fixed freeze-cycle duration
of 180–240 s followed by a bonus-freeze-cycle of the same
duration following successful PVI [1, 3, 5, 8]. However,
collateral damage to extra cardiac structures such as
phrenic nerve palsy (PNP) and esophageal thermal injury is
related to minimal balloon and esophageal temperatures as
well as to freeze-cycle durations and freeze-cycle numbers
[9, 10]. To prevent damage to extra cardiac structures,
shorter freeze-cycle durations and omitting the bonus-
freeze-cycle were suggested [2, 4]. However, no direct
comparison with regard to long-term clinical outcome and
the safety profile of bonus-freeze and no bonus-freeze
protocols have been performed yet. Therefore, the impact
of the bonus-freeze-cycle remains to be evaluated. The
current study investigates the long-term clinical outcome
following CB2-based PVI applying two different ablation
strategies: bonus-freeze and no bonus-freeze application
following successful PVI and evaluates the safety profile of
both ablation strategies.
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Methods
Patient characteristics and study design
Consecutive patients with symptomatic, drug-refractory
PAF or short-standing PersAF (duration of B3 months)
were admitted and consented for CB2-based PVI. Exclu-
sion criteria were prior left atrial (LA) ablation, LA
diameter[60 mm, severe valvular heart disease or con-
traindications to postinterventional oral anticoagulation.
Transesophageal echocardiography was performed prior to
ablation in all patients to assess the LA diameter and to rule
out intracardiac thrombi. No additional preprocedural
imaging was performed. All patients gave written informed
consent and all patient information was anonymized. The
study was approved by the local ethic’s board and has been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments.
Intraprocedural management
All procedures were performed under deep sedation using
midazolam, fentanyl, and propofol. Prior to transseptal
puncture, two diagnostic catheters were introduced via the
right femoral vein and positioned within the coronary sinus
and along the His-bundle. Single transseptal puncture was
performed under fluoroscopic guidance using a modified
Brockenbrough technique and an 8.5F transseptal sheath
(SL1, St. Jude Medical, Inc., St. Paul, MN, USA). The
transseptal sheath was exchanged over a wire for a 12F
steerable sheath (Flexcath Advance, Medtronic, Inc.,
Minneapolis, MN, USA). Heparin bolus were administered
targeting an activated clotting time of[300 s. Subse-
quently, selective PV angiographies were performed to
identify the individual PV ostia. A temperature probe
(Sensitherm, St. Jude Medical) was placed within the
esophagus at the level of the individual CB2 position to
monitor esophageal temperatures during the freeze-cycles.
The intraluminal esophageal temperature cut-off was set at
15 C [2].
PVI using the second-generation 28 mm CB
The CB2 was advanced into the LA over a modified spiral
mapping catheter (15 or 20 mm diameter; AchieveTM,
Medtronic, Inc., Minneapolis, MN, USA). The CB2 was
inflated proximal to the PV ostium followed by gentle push
aiming for complete sealing at the antral aspect of the PV.
Contrast medium injected through the central lumen of the
CB2 was used to verify complete PV occlusion. This was
followed by a freeze-cycle of 240 s. After successful PVI
one additional bonus-freeze-cycle of 240 ms duration was
applied in the first 60 patients, while the bonus-freeze-cycle
was omitted in the following 60 patients. Prior to each CB2
application a selective PV angiography was performed to
ensure the correct CB2 position at the PV ostium and
complete PV occlusion. Electrical isolation of the PVs was
always performed in the same order: left superior PV
(LSPV) followed by the left inferior PV (LIPV), right
superior PV (RSPV) and the right inferior PV (RIPV). The
procedural endpoint was defined as persistent PVI verified
by spiral mapping catheter recordings 30 min after the last
energy application.
Phrenic nerve pacing
During CB2 application along the septal PVs continuous
pacing of the phrenic nerve was performed using a diag-
nostic catheter positioned within the superior vena cava
(7F, Webster TM, Biosense Webster, Inc.) [2]. Pacing was
set at maximum output and pulse width (12 mA, 2.9 ms)
and a cycle length of 1200 ms. Phrenic nerve capture was
monitored by tactile feedback of diaphragmatic contraction
and assessment of the right diaphragmatic compound
motor action potential (CMAP) [11, 12]. Energy delivery
was interrupted immediately if weakening or loss of
diaphragmatic contraction was noted or a decrease of the
CMAP amplitude of C30 % was observed. In case of
catheter dislodgement, the pacing catheter was repositioned
until phrenic nerve capture was re-obtained. In case of
persistent PNP, no further cryoenergy was delivered along
the septal PVs.
Postprocedural care
Following PVI, all patients underwent transthoracic
echocardiography to rule out pericardial effusion. All
patients were treated with proton-pump inhibitors twice
daily for 6 weeks. Low molecular-weight heparin was
administered in patients on vitamin K antagonists and an
INR\2.0 until a therapeutic INR of 2–3 was achieved.
Novel oral anticoagulants were reinitiated 6 h post abla-
tion. Anticoagulation was continued for at least 3 months
and thereafter based on the individual CHA2DS2-VASC-
score. Previously ineffective antiarrhythmic drugs were
continued for 3 months.
Repeat procedures
In patients admitted for a repeat procedure due to
recurrence of atrial arrhythmia, venous access and
transseptal puncture were performed as previously
described. The presence or absence of electrical
Clin Res Cardiol (2016) 105:774–782 775
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activation of the PVs was assessed using a spiral map-
ping catheter. An electroanatomical LA map (CartoTM,
Biosense Webster) was generated and the PV ostia were
tagged. Identified reconduction gaps were closed by
irrigated radiofrequency (RF) ablation using a 3.5 mm
irrigated-tip catheter (Biosense Webster, Navi-StarTM,
Thermo-CoolTM). The procedural endpoint was complete
electrical PVI [13]. In patients with persistent isolation
of all PVs admitted in SR, fractionated ostial potentials
along previously performed ablation lines were identified
and ablated and/or linear lesion sets were applied. In
patients admitted in AF or atrial tachycardia (AT) and
persistent isolation of all PVs, ostial potentials were
identified and ablated followed by ablation of complex
fractionated atrial electrograms and deployment of linear
lesion sets in case of conversion to an AT [13].
Follow-up
Patients completed outpatient clinic visits at 3, 6,
12 months and in 6-months intervals thereafter including
12-lead surface ECG and 24 h-Holter ECGs. In addition,
regular telephonic interviews were performed. Additional
outpatient clinic visits were immediately initiated in case
of symptoms suggestive for recurrent arrhythmia [1–3].
The primary endpoint was defined as recurrence of any
symptomatic or documented atrial arrhythmia[30 s fol-
lowing a blanking period of 3 months. Secondary end-
points were defined as procedure related complications
such as PNP, cerebral embolism or atrioesophageal
fistula.
Statistical analysis
Differences of metric variables between the two groups
were analyzed with t test if the data were normally dis-
tributed, and with Wilcoxon–Mann–Whitney test other-
wise. Differences between categorical variables were
evaluated using the Chi square test or the Fisher’s exact test
in case of small expected cell frequencies. PV related data
were analyzed with (generalized) linear mixed models. For
patient related data the Wilcoxon test (contrast) and Fish-
er’s exact tests (phrenic nerve palsy and pericardial effu-
sion) were used. Linear mixed models were used for
continuous data. Generalized linear mixed models were
applied for binary or count data. A hierarchical logistic
regression model was consulted for binary data. A poisson
distribution was assumed for count data. All p values are
two-sided and a p value\ 0.05 was considered significant.
All calculations were performed with the statistical anal-
ysis software SAS (SAS Institute Inc., version 9.3, Cary,
NC, USA) [1–3].
Results
Patient characteristics
A total of 120 patients with PAF [95/120 (79 %)] or short-
standing (\3 months duration) PersAF [25/120 (21 %)]
underwent CB2-based PVI. No differences in baseline
characteristics were found between the groups (Table 1). In
the first 60 patients a bonus-freeze-cycle was applied fol-
lowing successful PVI (group 1) while in the following 60
patients the bonus-freeze-cycle was omitted (group 2)
(Fig. 1).
Acute ablation results
In patients of group 1 231 PVs were identified [60
RSPVs, 60 RIPVs, 57 LSPVs, 57 LIPVs and 3 left
common PVs (LCPV)] (Table 2). A total of 230/231
(99 %) PVs were successfully isolated. One RIPV was
not targeted due to PNP during CB2 ablation along the
RSPV. In patients of group 2 237 PVs were identified (60
RSPVs, 60 RIPVs, 51 LSPVs, 51 LIPVs and 9 LCPVs)
and a total of 235/237 (99 %) PVs were successfully
isolated. Two RIPV were not targeted due to PNP during
CB2 application of the ipsilateral RSPV. The median (1st,
3rd quartile) number of total freeze-cycles was 2 (2, 2)
for group 1 and 1 (1, 1) for group 2 (p\ 0.001), while
the median number of freeze-cycles to PVI was equal for
both groups 1 (1, 1) group 1 and 1 (1, 1) for group 2
(p = 0.24). The minimal ballon temperature was found to
be significantly different with -51.1 ± 6 C (group 1)
and -48.2 ± 6 C (group 2), (p\ 0.001). Real-time PVI
was visualized in 102/230 (44 %) and 102/235 (43 %) of
targeted PVs in patients of group 1 and group 2,
respectively (p = 0.85). No differences were found for
the median (1st, 3rd quartile) time to PVI between the
two groups (group 1 = 40 (27, 65 s) and group 2 38 (28,
55), p = 0.32.
The mean procedure time was 138.2 ± 29 min (group
1) and 113.8 ± 32 min (group 2), (p = 0.03), while fluo-
roscopy time was 24.3 ± 8 min (group 1) and
19.2 ± 6 min (group 2), (p = 0.03). The amount of
injected contrast medium was 160 ml (150, 200) and
120 ml (100, 140), respectively (p\ 0.001).
Complications
PNP occured in 2/60 (3 %) patients of group 1 and 3/60
(5 %) of group 2 (p = 1.00). Two PNP recovered within
10 months post ablation, another 2 PNP within
12 months and 1 PNP had fully recovered after
18 months. In 1/60 (1.7 %) patient of group 2 a
776 Clin Res Cardiol (2016) 105:774–782
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pericardial tamponade occured following isolation all
PVs most likely due to a difficult transseptal puncture.
Pericardiocentesis was performed and the patient was
discharged 2 days post ablation. No symptomatic PV
stenosis, cerebral embolism, or atrioesophageal fistula
occurred in any patient.
Clinical follow-up
Clinical follow-up was obtained in 117/120 (98 %)
patients, while 3/120 (2 %) patients were lost to follow-up
(1 patient of group 1, 2 patients of group 2). Mean follow-
up duration was 849 ± 74 (group 1) and 848 ± 101 days
Table 1 Baseline
characteristics
Group I
(bonus-freeze)
Group II
(no bonus-freeze)
p
Patients, n
Age (years)
60
62 ± 11
60
61 ± 11
0.84
Female gender, n (%) 24 (40) 22 (37) 0.24
Paroxysmal AF, n (%) 45 (75) 50 (83) 0.54
Short persistent AF, n (%) 15 (25) 10 (17) 0.54
Duration of AF (years) 36 ± 40 35 ± 31 0.31
LA-size (mm) 43 ± 5 42 ± 8 0.27
Arterial hypertension, n (%) 42 (70) 37 (62) 0.86
Diabetes mellitus, n (%) 8 (13) 5 (8) 0.36
Coronary artery disease, n (%) 6 (10) 9 (15) 0.10
Prior stroke, n (%) 3 (5) 5 (8) 0.11
Mean CHA2DS2-VASc-score 1.95 1.8 0.27
AF atrial fibrillation, LA left atrium
Fig. 1 Study flow chart. CB2
second-generation 28 mm
cryoballoon, PVI pulmonary
vein isolation
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(group 2, p = 0.13), respectively. A total of 42/59 (69 %)
patients (group 1) and 41/58 (67 %) patients (group 2)
remained in stable sinus rhythm during follow-up
(p = 0.69). Eighteen out of 59 (31 %) patients of group 1
suffered from recurrence of atrial arrhythmias: 8/18 (44 %)
patients PAF, 7/18 (39 %) patients PersAF and 3/18 (17 %)
patients AT. Nineteen out of 58 (33 %) patients of group 2
presented with atrial arrhythmia recurrences 7/19 (37 %)
patients PAF, 9/19 (47 %) patients PersAF and 3/19 (16 %)
patients AT (Fig. 2).
Findings during re-ablation procedures
A total of 26/34 (76 %) patients suffering from atrial
arrhythmia recurrences underwent a second ablation pro-
cedure using RF energy (group 1: 12/18, 67 % and group 2:
Table 2 Comparison of
procedural data
Group I
(bonus-freeze)
Group II
(no bonus-freeze)
p
Number of PVs, n 231 237
Total CB cycles per PV 2 (2, 2) 1 (1, 1) \0.001
Total CB cycles per PV until PVI 1 (1, 1) 1 (1, 1) 0.24
Number of isolated PVs, n (%) 230/231 (99) 235/237 (99) 0.66
Minimal CB2 temperature (C) -51.1 ± 6 -48.2 ± 6 \0.001
Minimal esophageal temp. (C) 34.6 (31, 36) 35.3 (34, 36) 0.05
Time to PVI (s) 40 (27, 65) 38 (28, 55) 0.32
Procedure time (min) 138.2 ± 29 113.8 ± 32 0.03
Fluoroscopy time (min) 24.3 ± 8 19.2 ± 6 0.02
Amount of contrast medium (ml) 160 (150, 200) 120 (100, 140) \0.001
Phrenic nerve palsy, n (%) 2 (3) 3 (5) 1.00
Values are expressed as mean and SD if data were normally distributed or as median (1st, 3rd quartile)
PV(s) Pulmonary vein(s), CB2 second-generation 28 mm cryoballoon, PVI pulmonary vein isolation
Fig. 2 The Kaplan–Meier curve demonstrates the relative proportion
of patients in stable sinus rhythm following index pulmonary vein
isolation using the second-generation 28 mm cryoballoon during a
follow-up period of 849 ± 74 (group 1) and 848 ± 101 days (group
2, p = 0.13). 69 % of patients (group 1) and 67 % of patients (group
2) remained in stable sinus rhythm during the follow-up period
(p = 0.69)
778 Clin Res Cardiol (2016) 105:774–782
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14/19, 74 %). Procedural data of the second ablation
attempt was available in 11/12 (92 %) patients of group 1
and 14/14 (100 %) patients of group 2. In a total of 27/98
(28 %) PVs, LA-to-PV reconduction was demonstrated.
The LA-to-PV reconduction rate was comparable for
patients of group 1 (15/43 PVs, 35 %) and group 2 (12/55
Fig. 3 Location of electrical
reconduction gaps. The
figure depicts the number and
location of reconduction gaps
identified during re-ablation
procedures. a Findings for
group 1 (bonus-freeze protocol),
b findings for group 2 (no
bonus-freeze protocol). Septal
and lateral pulmonary vein ostia
are divided into four segments
(antero-superior, antero-inferior,
postero-superior, postero-
inferior). Numbers express
reconduction gaps found for
each segment. No gaps were
found along the carina between
the ipsilateral pulmonary veins.
Data for a single left common
pulmonary vein is not shown
(each group n = 1 single left
common pulmonary vein, each
with one gap. RSPV right
superior pulmonary vein, RIPV
right inferior pulmonary vein,
LSPV left superior pulmonary
vein, LIPV left inferior
pulmonary vein)
Clin Res Cardiol (2016) 105:774–782 779
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PVs, 22 %) (p = 0.16). In total, 27 reconduction gaps were
identified (group 1: n = 15, group 2: n = 12) and dis-
tributed as shown in Fig. 3. Of note, no gap was found
along the inter-PV section. Re-isolation of all PVs was
successfully performed using RF energy. In 17/25 (68 %)
patients [group 1: 7/11 (64 %), group 2: 10/14 (71 %)],
ablation of PV reconduction gaps was conducted. In
addition, ablation of ostial potentials was performed in
13/25 (52 %) patients [group 1: 2/11 (18 %), group 2: 3/14
(21 %)], ablation of complex fractionated atrial electro-
grams in 3/25 (12 %) patients [group 1: 1/11 (9 %), group
2: 2/14 (14 %)], and linear lesion ablation in 6/25 (24 %)
patients. A mitral isthmus line ablation was performed in
1/11 (9 %) patients of group 1 and 2/14 (14 %) patients of
group 2 while ablation of an anterior line was conducted in
1/11 (9 %) patients of group 1 and 2/14 (14 %) patients of
group 2. Ablation of the cavo-tricuspid isthmus (CTI) was
conducted in 6/25 (24 %) patients [group 1: 3/11 (27 %),
group 2: 3/14 (21 %)] due to documented typical CTI-
dependent atrial flutter. Periprocedural stroke occurred in
1/25 (4 %) patient of group 1. No further complications
were documented.
Discussion
To the best of our knowledge, the current study is the first
to compare long-term clinical outcome and procedural
characteristics of a bonus-freeze protocol and a no bonus-
freeze protocol in CB2-based PVI. The study could
demonstrate that omitting the bonus-freeze-cycle results in
comparable clinical outcome data and significantly shorter
procedure and fluoroscopy times without differences in the
safety profile.
Current CB2 ablation strategies are mainly based on
fixed freeze-cycle durations and mostly include a cus-
tomized bonus-freeze-cycle following successful PVI [1, 5,
14]. However, recent publications suggest that omitting the
bonus-freeze-cycle after successful PVI might be equally
effective with regard to clinical outcome [2, 4]. While one-
year clinical outcome in protocols that include a bonus-
freeze-cycle range between 76.8 and 83.6 %, [1, 5, 8]
slendered protocols without a bonus-freeze-cycle also
report on 80.4 to 82 % 1-year clinical efficacy [2, 4].
Furthermore no differences were reported for durability
PVI comparing a bonus- and a no bonus-freeze protocol in
repeat procedures [13]. Additionally, our recent work
demonstrated this observation in a smaller patients popu-
lation. However, except a single study with limited follow-
up duration, there are currently no publications in a head-
to-head fashion comparing both strategies with regard to
long-term clinical outcome [15].
Reducing the number of freeze-cycles and/or the freeze-
cycle durations might not only affect clinical outcome of
CB2 ablation but might also have a beneficial impact on its
safety profile. Characteristic complications in CB2 ablation
are PNP [9, 11, 16, 17] and thermal oesophageal lesions
[18, 19]. Reduction in energy transfer might reduce the
incidence of these complications and will simultaneously
shorten procedure and fluoroscopy times and reduce radi-
ation exposure. In the current study we could demonstrate
significantly shorter procedure and fluoroscopy times as
well as lower amounts of applied contrast media in the no
bonus-freeze group, while long-term clinical outcome data
was similar in both groups. Accordingly, our data support
the hypothesis that the necessity of a bonus-freeze appli-
cation after successful PVI is questionable. Although our
study did not reveal a significant difference in periproce-
dural complications when omitting the bonus-freeze-cycle,
it also failed to prove potential benefits of a bonus-freeze-
cycle strategy with regard to clinical outcome.
Further studies will also have to evaluate and potentially
include the individual time to isolation (TTI) as revealed
by the Achieve-catheter. In some studies an increased
incidence of online PV recordings was demonstrated when
comparing the first-generation cryoballoon (Arctic Front,
Medtronic) with the CB2 [20, 21]. In a recent study we
could additionally demonstrate a significantly increased
incidence of online PV recordings when using the recently
launched third-generation CB (Arctic Front Advance ST,
Medtronic) as compared to the CB2, thus facilitating the
consideration of the individual TTI [22]. Future studies will
focus on the TTI and thus on ablation strategies with
individualized freeze-cycle durations considering the TTI.
These potentially shorter freeze-cycles might further affect
the safety profile but will also have to demonstrate equal
clinical efficacy.
Limitations
The presented findings are based on a single-center
experience enrolling only a limited number of patients in
a non-randomized fashion. However, the baseline char-
acteristics in the current study are not different between
the groups. The data is based on a retrospective analysis
and the follow-up was limited to 24 h-Holter ECGs. This
limitation might overestimate the overall success rate
after CB2 ablation. Furthermore, the rate of complica-
tions utilizing the CB2 is considerably low in both
groups. Therefore, higher patient numbers will be nec-
essary to detect differences in periprocedural complica-
tions when applying a bonus-freeze versus a no bonus-
freeze ablation protocol.
780 Clin Res Cardiol (2016) 105:774–782
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Conclusions
The two-year freedom from atrial arrhythmia recurrences
after CB2-based PVI is 69 % for the bonus-freeze and
67 % for the no bonus-freeze protocol. Procedure and
fluoroscopy times, radiation exposure and the amount of
applied contrast medium are significantly reduced when
omitting the bonus-freeze application. No differences in
periprocedural complications were detected. These findings
suggest that a bonus-freeze application may not be essen-
tial for CB2 based PVI procedures.
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